LINC 2025
The LINC 2025 congress has finished few days ago and it has been an incredible and very successful edition for CID.
- During the 1st congress day, in the main Arena1, Dr. Angelo Cioppa (Mercogliano Hospital- Italy) has released - for the first time ever - the clinical data of complex patients with SFA disease treated with the implant of NiTiDES™, our unique CID SX DES releasing Sirolimus for SFA|P1. This challenging and independent study has underlined how the NiTiDES™ innovative technology can help advancing the clinical outcome of complex patients with complex SFA lesions (91,5% freedom from TLR at 1 year and 0% HALO!).
- During the 3rd congress day, again in the main Arena1, Dr. Elena Herrero Martínez (Jaén hospital – Spain) has presented the latest results of Jaén study in the BTK area. This independent and physician initiated trial has confirmed that Cre8™ BTK is a very effective option for everyday patients with CLTI and complex/calcified lesions with un-paralleled clinical outcome to date (87,2% patency at 1y/ 80,5% patency at 2y) strengthening that the role of balloon-expandable DES in BTK should change: from bail-out to primary stenting!
